V
Virdante Pharmaceuticals
A privately held biopharmaceutical company focused on the development and commercialization of drugs for autoimmune and inflammatory disorders
About Virdante Pharmaceuticals
Virdante Pharmaceuticals was a biopharmaceutical firm concentrated on creating treatments for autoimmune and inflammatory diseases. The company was established in 2007, though some sources state 2008, and was previously known as Centaurus Pharmaceuticals. It was founded by Dr. Jeffrey Ravetch, a professor at The Rockefeller University, who discovered the anti-inflammatory biological pathway that formed the basis of the company's core technology. Virdante secured an exclusive license for this technology from The Rockefeller University and formed a research alliance with Dr. Ravetch's lab. To lead the commercialization efforts, John Ripple, who previously served as CEO of Syntonix Pharmaceuticals, was brought on as CEO in 2008.
The company's central technology was the proprietary "sialic switch". This technology enhances the anti-inflammatory characteristics of antibodies by adding sialic acid to them, a process known as sialylation. The primary application was to increase the potency of intravenous immunoglobulin (IVIG), a plasma-derived product used for treating autoimmune disorders. By creating a more potent version, called sIVIG, Virdante aimed to dramatically reduce the dosage and administration time for patients, from days to a matter of hours. The business model involved purchasing IVIG on the market and applying its proprietary manufacturing step to produce sIVIG. The company was also developing a second product, a sialylated recombinant Fc fragment (sFc). The firm operated in the biopharmaceutical market, specifically targeting the multi-billion dollar market for plasma-derived IVIG products and other antibody therapeutics for autoimmune and inflammatory conditions.
Virdante Pharmaceuticals successfully raised significant capital to fund its research and development. It completed a Series A funding round totaling $47.75 million and a Series B round of $30.1 million. Key investors included Thomas, McNerney & Partners, Venrock, Clarus Ventures, MedImmune Ventures, Osage University Partners, and Biogen. In December 2011, Momenta Pharmaceuticals acquired Virdante's Sialic Switch assets, including intellectual property and cell lines, for an upfront payment of $4.5 million with potential milestone payments that could total $51.5 million. Following this transaction, Virdante began operating as a subsidiary of Momenta Pharmaceuticals.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Dec 2011 | $52M | $52M | Momenta Pharmaceuticals | — |
| LATE VCOther financing | Oct 2011 | $30M | $120M | Undisclosed | — |
Growth signals
Latest recorded traffic for Virdante Pharmaceuticals is 0 monthly website visits. Virdante Pharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Virdante Pharmaceuticals in the Cambridge ecosystem
The Virdante Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Venrock
Clarus Ventures
MedImmune Ventures
Osage University Partners
Biogen
Other known investors1 additional known investor
Momenta Pharmaceuticals
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Virdante Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Virdante Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










